Ronacaleret

DB05255InvestigationalSmall molecule

Ronacaleret is a calcium-sensing receptor antagonist.

Mechanism: 751689 is novel small molecules that work by antagonizing calcium-sensing receptors on the surface of the parathyroid gland, thereby triggering a transient release of the body's own stores of parathyroid hormone (PTH). This release of PTH may have the potential to rebuild the bone mass lost as a result of osteoporosis and improve overall bone microarchitecture in these patients.
Curator reviewed
Primary indication: Post-menopausal women with osteoporosisCurator reviewed
Formula / weight: C₂₅H₃₁F₂NO₄ · 447.523 g/mol (avg)

Resolves to

Compound

Structure

InChIKeyFQJISUPNMFRIFZ-HXUWFJFHSA-NSMILESCC(C)(CC1CC2=C(C1)C=CC=C2)NC[C@@H](O)COC1=CC(CCC(O)=O)=CC(F)=C1F

Targets

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ronacaleret, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.